We have constructed a second generation malaria transmission-blocking vaccine candidate based on Pfs25, the predominate surface protein of Plasmodium falciparum zygotes, to overcome potential production problems with the original construct. Four modifications were made: (1) addition of the last cysteine residue of the fourth epidermal growth factor like-domain of Pfs25; (2) mutagenesis of asparagine-linked glycosylation sites with glutamine rather than alanine; (3) addition of a six histidine tag at the carboxy-terminus for highly efficient purification of recombinant protein on nickel-NTA agarose; and (4) fermentation that combines continuous glucose fed-batch methodology with pH-controlled glucose addition and a terminal ethanol feed. The resulting product, TBV25H (Transmission-Blocking Vaccine based on Pfs25 with a Histidine tag), appears to be a more potent antigen and immunogen than the original construct, and the fermentation and post-fermentation processing methodology easily lend themselves to technology transfer to the ultimate users, newly industrialized countries.
Oaks, S.C., Mitchell, V.S., Pearson, G.W. and Carpenter, C.C.I. (Eds.) 1991. Malaria: Obstacles and opportunities: A report of the Committee for the Study on Malaria Prevention and Control. National Academy Press, Washington, D.C.
Kaslow, D.C. 1993. Transmission-blocking immunity against malaria and other vector-borne diseases. Curr. Opinion in Immunol. 5: 557–565.
Kaslow, D.C., Quakyi, I.A., Syin, C., Raum, M.G., Keister, D.B., Coligan, J.E., McCutchan, T.F. and Miller, L.H. 1988. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 333: 74–76.
Kaslow, D.C., Isaacs, S., Quakyi, I.A., Gwadz, R.W., Moss, B. and Keister, D.B. 1991. Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus. Science 252: 1310–1313.
Barr, P.J., Green, K.M., Gibson, H.L., Bathurst, I.C., Quakyi, I.A. and Kaslow, D.C. 1991. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J. Exp. Med. 174: 1203–1208.
Kaslow, D.C., Bathurst, I.C., Keister, D.B., Campbell, G.H., Adams, S., Morris, C.L., Sullivan, J.S., Barr, P.J. and Collins, W.E. 1993. Safety, immunogenicity and in vitro efficacy of a muramyl tripeptide-based malaria transmission-blocking vaccine in an Aotus nancymai monkey model. Vaccine Res. 2: 95–103.
Price, V., Mochizuki, D., March, C.J., Cosman, D., Deeley, M.C., Klinke, R., Clevenger, W., Gillis, S., Baker, P. and Urdal, D. 1987. Expression, purification and characterization of recombinant murine granulocyte-macrophage colony-stimulating factor and bovine interleukin-2 from yeast. Gene 55: 287–293.
Crowe, J. and Henco, K. 1992. The QIA expressionist. QIAGEN, Inc. Chats-worth, California.
Tøttrup, H.V. and Carlsen, S. 1990. A process for the production of human proinsulin in Saccharomyces cerevisiae. Biotech. Bioeng. 35: 339–348.
Porro, D., Martegani, E., Tura, E. and Ranzi, B.M. 1991. Development of a pH-controlled fed-batch system for budding yeast. Res. Microbiol. 142: 535–539.
Hochuli, E., Barnsworth, W., Döbeli, H., Gentz, R. and Sfuber, D. 1988. Genetic approach to facilitate purification of recombinant proteins with a novel metal chelate adsorbent. Bio/Technology 6: 1321–1325.
O'Shannessy, D.J., Voorstad, P.J. and Quarles, R.H. 1987. Quantitation of glycoproteins on electroblots using the biotin-streptavidin complex. Anal. Biochem. 163: 204–209.
Hancock, K. and Tsang, V.C.W. 1986. Development and optimization of the FAST-ELISA for detecting antibodies to Schistosoma mansoni. J. Immunol. Methods 92: 167–176.
Quakyi, I.A., Carter, R., Rener, J., Kumar, N., Good, M.F. and Miler, L.H. 1987. The 230-kD gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. J. Immunol. 139: 4213–4217.
About this article
Cite this article
Kaslow, D., Shiloach, J. Production, Purification and Immunogenicity of a Malaria Transmission-Blocking Vaccine Candidate: TBV25H Expressed in Yeast and Purified Using Nickel-NTA Agarose. Nat Biotechnol 12, 494–499 (1994). https://doi.org/10.1038/nbt0594-494
Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha
PLOS ONE (2019)
Infection and Immunity (2019)
Antibody-Dependent, Gamma Interferon-Independent Sterilizing Immunity Induced by a Subunit Malaria Vaccine
Infection and Immunity (2019)
FEMS Yeast Research (2019)
Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines
Scientific Reports (2017)